J. Kevin Buchi - 11 Aug 2023 Form 4 Insider Report for Benitec Biopharma Inc. (BNTC)

Role
Director
Signature
/s/ J. Kevin Buchi
Issuer symbol
BNTC
Transactions as of
11 Aug 2023
Net transactions value
$0
Form type
4
Filing time
14 Aug 2023, 17:10:56 UTC
Previous filing
13 Jun 2023
Next filing
07 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BNTC Common Stock Purchase +51,813 +18244% 52,097 11 Aug 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BNTC Common Warrants (right to buy) Purchase +51,813 51,813 11 Aug 2023 Common Stock 51,813 $3.86 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock, par value $0.0001 per share (the "Common Stock") purchased together with common warrants to purchase shares of Common Stock in the Issuer's registered underwritten offering on August 11, 2023 for a purchase price of $1.93.
F2 The reported number of shares has been adjusted to reflect the impact of the Issuer's 17-for-1 reverse stock split completed on July 26, 2023.